Juexian Song

Dr. Juexian Song


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
QGQian Guo
Qian Guo
XJXiaoqing Jiang
Xiaoqing Jiang
CNCan Ni
Can Ni
LLLinjing Li
Linjing Li
LCLi Chen
Li Chen
JSJuexian Song
Juexian Song
Acute ischemic stroke (AIS) is a major cause of acquired adult disability and death. Our previous studies proved the efficacy and effectiveness of Tanhuo decoction (THD) on AIS. However, the therapeutic mechanism remains unclear. We recruited 49 AIS patients and 30 healthy people to explore the effects of THD+basic treatment on the poststroke gut microbiota of AIS patients using 16S rRNA sequencing, in which 23 patients received basic treatment (control group) and 26 patients received THD+basic treatment (THD group). By comparing the data before and after treatments, we found the THD group acquired better outcome than the control group on both clinical outcome indices and the characteristics of gut microbiota. In addition to the mediation on short‐chain fatty acid‐ (SCFA‐) producing bacteria in two groups, treatment in the THD group significantly decreased the lipopolysaccharide‐ (LPS‐) producing bacteria to reduce LPS biosynthesis. Besides, the complexity of the cooccurrence of gut microbiota and the competition among LPS‐producing bacteria and opportunistic pathogenetic bacteria were enhanced in the THD group. Treatment in the THD group also exhibited the potential in decreasing genes on the biosynthesis of trimethylamine (TMA), the precursor of Trimethylamine N‐oxide (TMAO), and increasing genes on the degradation of TMA, especially increasing trimethylamine‐corrinoid protein Co‐methyltransferase (mttB) which catabolizes TMA to methane. These results hinted that THD+basic treatment might exert its efficacy by mediating the gut microbiota and microbial metabolites, including LPS and TMAO that aggravate the sterile inflammation and platelet aggregation. Moreover, the well‐fitting regression model results in predicting the clinical outcome with the alteration of gut microbiota proved gut microbiota as a potential indicator of AIS and provided evidence of the communication between the gut and brain of AIS patients.

9 February 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
QGQian Guo
Qian Guo
CNCan Ni
Can Ni
LLLinjing Li
Linjing Li
MLMo Li
Mo Li
XJXiaoqing Jiang
Xiaoqing Jiang
JSJuexian Song
Juexian Song
As a life-threatening disease, stroke is the leading cause of death and also induces adult disability worldwide. To investigate the efficacy of the integrated traditional Chinese medicine (ITCM) on the therapeutic effects of acute ischemic stroke (AIS) patients, we enrolled 26 patients in the ITCM [Tanhuo decoction (THD) + Western medicine (WM)] group and 23 in the WM group. Thirty healthy people were also included in the healthy control (HC) group. ITCM achieved better functional outcomes than WM, including significant reduction of the phlegm-heat syndrome and neurological impairment, and improvement of ability. These facts were observed in different pretreatment gut enterotypes. In this paper, we collected the stool samples of all participants and analyzed the 16S rRNA sequence data of the gut microbiota. We identified two enterotypes (Type-A and Type-B) of the gut microbial community in AIS samples before treatment. Compared to Type-B, Type-A was characterized by a high proportion of Bacteroides, relatively high diversity, and severe functional damage. In the ITCM treatment group, we observed better clinical efficacy and positive alterations in microbial diversity and beneficial bacterial abundance, and the effect of approaching healthy people’s gut microbiota, regardless of gut enterotypes identified in pretreatment. Furthermore, we detected several gut microbiota as potential therapeutic targets of ITCM treatment by analyzing the correlations between bacterial abundance alterations and functional outcomes, where Dorea with the strongest correlation was known to produce anti-inflammatory metabolite and negatively linked to trimethylamine-N-oxide (TMAO), a biomarker of AIS. This study analyzed clinical and gut microbial data and revealed the possibility of a broad application independent of the enterotypes, as well as the therapeutic targets of the ITCM in treating AIS patients with phlegm-heat syndrome.

27 October 2023 in Heliyon
Verified
Journal Article
Open access
WZWei Zhuang
Wei Zhuang
NSNan Sun
Nan Sun
CGChengjuan Gu
Chengjuan Gu
SLShimeng Liu
Shimeng Liu
YZYujiao Zheng
Yujiao Zheng
JSJuexian Song
Juexian Song
Aging is related to many factors, such as genes, oxidative damage, metabolic abnormalities, immune regulation and sex hormones. This article reviews the pharmacological mechanism of Epimedium on slow aging from six aspects: gene regulation, antioxidant, the regulation of metabolism, the modulation of the immune system, the regulation of sex hormone, and clinical efficacy. Aim of the studyThrough literature review, to discover the potential pharmacological mechanism of Epimedium for slow aging. We reviewed the literature on the applications of Epimedium in multiple systems and the potential underlying mechanisms with systematic and comprehensive illustrations. The review includes the following aspects: gene regulation, antioxidant, the regulation of metabolism, the modulation of the immune system, the regulation of sex hormone, clinical efficacy and safety. The slow aging active components of Epimedium may be flavonoids, such as Epimedins A, B, C and icariin The slow aging effect of Epimedium may be related to gene regulation, antioxidant, the regulation of metabolism, the modulation of the immune system, and the regulation of sex hormone. No severe adverse reaction has been reported. Epimedium has potential slow aging effect and been widely used in the clinic for aging-related diseases in the real world in China; however, large-scale studies are still needed.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DXDongjuan Xu
Dongjuan Xu
WZWenfeng Zhao
Wenfeng Zhao
JSJuexian Song
Juexian Song
LYLu Yin
Lu Yin
KWKun Wang
Kun Wang
HWHongxing Wang
Hongxing Wang
Objective. The role of trimethylamine N‐oxide (TMAO) in cardiovascular diseases has been highlighted. Nevertheless, the associations of large‐artery atherosclerotic (LAA) stroke with TMAO and blood lipid‐related indices are little investigated. Methods. A cross‐sectional comparative study was performed on 50 patients with LAA stroke and 50 healthy controls. Basic demographic data, common vascular risk factors, and blood lipid‐related indices were collected. Plasma TMAO was detected through liquid chromatography tandem mass spectrometry. Multivariable unconditional logistic regression analyses were run to assess the associations of LAA stroke with plasma TMAO level and blood lipid‐related indices. The area under the curve (AUC) of the receiver operating characteristic (ROC) was computed to assess the diagnostic performance of plasma TMAO level and blood lipid‐related indices for LAA stroke. Results. Compared with healthy controls, the elevated plasma TMAO level (odds ratio [OR], 7.03; 95% confidence interval [CI], 2.86, 17.25; p < 0.01) and Apo‐B (OR, 1.74; 95% CI, 1.06, 2.85; p = 0.03) were observed in LAA stroke patients, while lower Apo‐A1 (OR, 0.56; 95% CI, 0.34, 0.91; p = 0.02), Apo‐A1 to Apo‐B ratio (OR, 0.29; 95% CI, 0.15, 0.56; p < 0.01), and HDL‐C (OR, 0.56; 95% CI, 0.35, 0.91; p = 0.02) were found in LAA stroke patients after adjusted for age and gender. Moreover, plasma TMAO (AUC, 0.89; 95% CI, 0.83, 0.95), Apo‐A1 (AUC, 0.81; 95% CI, 0.72, 0.89), Apo‐B (AUC, 0.81; 95% CI, 0.73, 0.90), Apo‐A1 to Apo‐B ratio (AUC, 0.85; 95% CI, 0.78, 0.93), and HDL‐C (AUC, 0.81; 95% CI, 0.72, 0.89) showed good diagnostic values for LAA stroke in adjusted models. Conclusions. The plasma TMAO level, Apo‐A1, Apo‐B, and HDL‐C are important biomarkers for LAA stroke patients.

4 December 2020 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
JSJuexian Song
Juexian Song
YNYuting Nie
Yuting Nie
PWPingping Wang
Pingping Wang
HLHuiqiang Lu
Huiqiang Lu
LGLi Gao
Li Gao
Objectives: Surgical treatment is expected to remove clot immediately in acute spontaneous intracerebral hemorrhage (SICH) patients. The aim of this study was to evaluate whether Naoxueshu could enhance the efficacy of clot removal surgery in acute SICH patients.Methods: One hundred twenty patients who had been diagnosed as SICH according to neuroimaging were enrolled in this study. They received craniotomy, decompressive craniectomy, or minimally invasive surgical evacuation as appropriate and then were randomized into two groups: the Naoxueshu group (NXS group, n = 60) and the control group (n = 60). All the patients received standard medical management while patients in NXS group also took Naoxueshu oral liquid 10 ml with three times a day for seven consecutive days. The primary outcome was the 7‐day hematoma volume and secondary outcomes were 7‐day National Institutes of Health Stroke Scale (NIHSS) score and 7‐day cerebral edema score.Results: After clot removal surgery, hematoma volume in NXS group (9.5 ± 8.0) was significantly decreased than that in Control group (21.3 ± 22.9, p < .0001) 7 days after surgery. Moreover, cerebral edema was also relieved after 7‐day's Naoxueshu treatment (2.5 ± 0.9 vs. 2.9 ± 0.7, p = .043). Since patients in NXS group had worse baseline NIHSS score (17.2 ± 8.1 vs. 13.7 ± 10.1, p = .039), it was reasonable to conclude that Naoxueshu treatment could improve patients’ neurological function because 7‐day NIHSS score of the two groups was similar.Conclusion: Naoxueshu oral liquid could relieve hematoma volume and cerebral edema after clot removal surgery in acute SICH patients. Moreover, it had the potential to improve patients’ short‐term neurological function.

4 August 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XYXiongwu Yu
Xiongwu Yu
LHLingqian He
Lingqian He
QWQi Wang
Qi Wang
ZZZhongyun Zhang
Zhongyun Zhang
HZHuaiqiu Zhu
Huaiqiu Zhu
JSJuexian Song
Juexian Song
Integrating Chinese medicine and biomedicine for treating acute ischemic stroke (AIS) presents a promising strategy. Accurately predicting Traditional Chinese Medicine (TCM) heat syndrome types in AIS patients is crucial for guiding appropriate medication use within this combined treatment strategy. In this study, a clinical cohort including TCM syndromes, laboratory markers, and baseline assessments, were collected from 193 AIS patients. We developed a deep learning method with Convolutional Neural Networks (CNNs) to predict heat syndrome types in AIS patients by integrating TCM pattern characteristics and laboratory indicators. Feature importance was assessed using SHapley Additive exPlanations (SHAP) and permutation importance, and partial dependence plots (PDP) were used to explore the relationships between features and predictions. The model with the comprehensive feature dataset achieved an accuracy of 0.95, F1 score of 0.95, and AUC of 0.91 on the test set, exhibiting better performance overall compared to predictions based solely on TCM pattern characteristics or laboratory indicators. Key factors associated with the heat syndrome types included Tongue Teeth Marks, Stool, Sweat, Tongue Fissures, glycated hemoglobin (HbA1c), triglycerides (TG), fasting blood glucose (FBG) and total cholesterol (CHO). In conclusion, this study confirms the effectiveness of the CNN model in predicting heat syndrome types in AIS patients when incorporating TCM patterns with biochemical laboratory indicators.